STOCK GOODIES PLAYS OF THE WEEK

[goodibag]

OMHE_Developed_Marijuana_based_Pain_Treatment_Starting_FDA_Approval_Process

From 12/05/2017 MMJ Medicine Development & FDA Approval Plan News

Based on four decades of exemplary care, Omni Health has started the process of reformulating its most successful proprietary formularies to include cannabidiol (CBD) and commence its FDA Medical Devices registration for topical pain analgesic. It is Omni Health’s intent to capitalize on a significant potential for cannabinoid bio therapeutics to transform the treatment of chronic pain and other debilitating conditions, and bring a product to the market with a strong demand and reimbursable under government payors and major insurance plans.

(1) In Feb 2017 OMHE shared its vision and indicated its plan on working on therapeutic cannabis products and licensed medical marijuana cultivation.
CLICK HERE TO READ FEB 2017 OMHE VISION & FUTURE PLANS

(2) In My 2017 OMHE announced the opening of its Biotech R&D Lab.
CLICK HERE TO READ MAY 2017 LAB ANNOUNCEMENT

(3) In June 2017 Biotech scientists with FDA/regulatory approval joined OMHE.
CLICK HERE TO READ JUNE 2017 SCIENTISTS ANNOUNCEMENT

(4) In Nov 2017 OMHE updated about cannabinoid-based drug-development.
CLICK HERE TO READ NOV 2017 DRUG DEVELOPMENT UPDTE

(5) Now in Dec 2017 OMHE announced its plan already in motion to create a drug candidate compelling to Big Pharma, development of cannabidiol pain treatment therapeutic & medicine and filing of FDA registration by employing an FDA regulations-savvy, ‘fast-track’ pipeline strategy.
CLICK HERE TO READ DEC 2017 FDA REGISTRATION UPDATE






OMHE PPS Ready to Rise to $1